<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35895140</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>144</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>HNRNPK alleviates RNA toxicity by counteracting DNA damage in C9orf72 ALS.</ArticleTitle><Pagination><StartPage>465</StartPage><EndPage>488</EndPage><MedlinePgn>465-488</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-022-02471-y</ELocationID><Abstract><AbstractText>A 'GGGGCC' repeat expansion in the first intron of the C9orf72 gene is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The exact mechanism resulting in these neurodegenerative diseases remains elusive, but C9 repeat RNA toxicity has been implicated as a gain-of-function mechanism. Our aim was to use a zebrafish model for C9orf72 RNA toxicity to identify modifiers of the ALS-linked phenotype. We discovered that the RNA-binding protein heterogeneous nuclear ribonucleoprotein K (HNRNPK) reverses the toxicity of both sense and antisense repeat RNA, which is dependent on its subcellular localization and RNA recognition, and not on C9orf72 repeat RNA binding. We observed HNRNPK cytoplasmic mislocalization in C9orf72 ALS patient fibroblasts, induced pluripotent stem cell (iPSC)-derived motor neurons and post-mortem motor cortex and spinal cord, in line with a disrupted HNRNPK function in C9orf72 ALS. In C9orf72 ALS/FTD patient tissue, we discovered an increased nuclear translocation, but reduced expression of ribonucleotide reductase regulatory subunit M2 (RRM2), a downstream target of HNRNPK involved in the DNA damage response. Last but not least, we showed that increasing the expression of HNRNPK or RRM2 was sufficient to mitigate DNA damage in our C9orf72 RNA toxicity zebrafish model. Overall, our study strengthens the relevance of RNA toxicity as a pathogenic mechanism in C9orf72 ALS and demonstrates its link with an aberrant DNA damage response, opening novel therapeutic avenues for C9orf72 ALS/FTD.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Braems</LastName><ForeName>Elke</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-6158-9208</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), KU Leuven-University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain &amp; Disease Research, Laboratory of Neurobiology, VIB, Campus Gasthuisberg, O&amp;N5, Herestraat 49, PB 602, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bercier</LastName><ForeName>Val&#xe9;rie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), KU Leuven-University of Leuven, Leuven, Belgium. valerie.bercier@kuleuven.be.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain &amp; Disease Research, Laboratory of Neurobiology, VIB, Campus Gasthuisberg, O&amp;N5, Herestraat 49, PB 602, 3000, Leuven, Belgium. valerie.bercier@kuleuven.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Schoor</LastName><ForeName>Evelien</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), KU Leuven-University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain &amp; Disease Research, Laboratory of Neurobiology, VIB, Campus Gasthuisberg, O&amp;N5, Herestraat 49, PB 602, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Imaging and Pathology, Laboratory of Neuropathology and Leuven Brain Institute (LBI), KU Leuven-University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heeren</LastName><ForeName>Kara</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), KU Leuven-University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain &amp; Disease Research, Laboratory of Neurobiology, VIB, Campus Gasthuisberg, O&amp;N5, Herestraat 49, PB 602, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beckers</LastName><ForeName>Jimmy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), KU Leuven-University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain &amp; Disease Research, Laboratory of Neurobiology, VIB, Campus Gasthuisberg, O&amp;N5, Herestraat 49, PB 602, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fumagalli</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), KU Leuven-University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain &amp; Disease Research, Laboratory of Neurobiology, VIB, Campus Gasthuisberg, O&amp;N5, Herestraat 49, PB 602, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dedeene</LastName><ForeName>Lieselot</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), KU Leuven-University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain &amp; Disease Research, Laboratory of Neurobiology, VIB, Campus Gasthuisberg, O&amp;N5, Herestraat 49, PB 602, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Imaging and Pathology, Laboratory of Neuropathology and Leuven Brain Institute (LBI), KU Leuven-University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Laboratory for Molecular Neurobiomarker Research and Leuven Brain Institute (LBI), KU Leuven-University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moisse</LastName><ForeName>Matthieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), KU Leuven-University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain &amp; Disease Research, Laboratory of Neurobiology, VIB, Campus Gasthuisberg, O&amp;N5, Herestraat 49, PB 602, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geudens</LastName><ForeName>Ilse</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), KU Leuven-University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain &amp; Disease Research, Laboratory of Neurobiology, VIB, Campus Gasthuisberg, O&amp;N5, Herestraat 49, PB 602, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hersmus</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), KU Leuven-University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain &amp; Disease Research, Laboratory of Neurobiology, VIB, Campus Gasthuisberg, O&amp;N5, Herestraat 49, PB 602, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Arpan R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selvaraj</LastName><ForeName>Bhuvaneish T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandran</LastName><ForeName>Siddharthan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Ritchie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cedars-Sinai Medical Center, Board of Governors Regenerative Medicine Institute, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Dietmar R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Imaging and Pathology, Laboratory of Neuropathology and Leuven Brain Institute (LBI), KU Leuven-University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), KU Leuven-University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain &amp; Disease Research, Laboratory of Neurobiology, VIB, Campus Gasthuisberg, O&amp;N5, Herestraat 49, PB 602, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swinnen</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), KU Leuven-University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain &amp; Disease Research, Laboratory of Neurobiology, VIB, Campus Gasthuisberg, O&amp;N5, Herestraat 49, PB 602, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Den Bosch</LastName><ForeName>Ludo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), KU Leuven-University of Leuven, Leuven, Belgium. ludo.vandenbosch@kuleuven.be.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain &amp; Disease Research, Laboratory of Neurobiology, VIB, Campus Gasthuisberg, O&amp;N5, Herestraat 49, PB 602, 3000, Leuven, Belgium. ludo.vandenbosch@kuleuven.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_EX_MR/N50192X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R001162/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034641">Heterogeneous-Nuclear Ribonucleoprotein K</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016372">RNA, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004249" MajorTopicYN="N">DNA Damage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034641" MajorTopicYN="N">Heterogeneous-Nuclear Ribonucleoprotein K</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020774" MajorTopicYN="Y">Pick Disease of the Brain</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016372" MajorTopicYN="N">RNA, Antisense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015027" MajorTopicYN="N">Zebrafish</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">DNA damage</Keyword><Keyword MajorTopicYN="N">HNRNPK</Keyword><Keyword MajorTopicYN="N">RNA toxicity</Keyword><Keyword MajorTopicYN="N">RRM2</Keyword></KeywordList><CoiStatement>L.V.D.B. received speaker honorary from UCB (Brussels, Belgium) and Gr&#xfc;nenthal (Aachen, Germany), is head of the Scientific Advisory Board of Augustine Therapeutics (Leuven, Belgium) and is part of the Investment Advisory Board of Droia Ventures (Meise, Belgium). D.R.T. received speaker honorary or travel reimbursement from Novartis Pharma AG (Basel, Switzerland), UCB (Brussels, Belgium) and GE Healthcare (Amersham, UK) and collaborated with Novartis Pharma AG (Basel, Switzerland), Probiodrug (Halle (Saale), Germany), GE Healthcare (Amersham, UK) and Janssen Pharmaceutical Companies (Beerse, Belgium). D.R.T. serves in the editorial board of Acta Neuropathologica, but was not involved in the handling of this manuscript at any stage. P.V.D. participated in advisory board meetings of Biogen (Cambridge, MA, US), Cytokinetics (San Francisco, CA, US), Ferrer (Barcelona, Spain), UCB (Brussels, Belgium), Argenx (Ghent, Belgium), Muna Therapeutics (Copenhagen, Denmark), Alector (San Francisco, CA, US), Augustine Therapeutics (Leuven, Belgium), Alexion Therapeutics (Boston, MA, US) and QurAlis (Cambridge, MA, US).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>27</Day><Hour>11</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35895140</ArticleId><ArticleId IdType="pmc">PMC9381635</ArticleId><ArticleId IdType="doi">10.1007/s00401-022-02471-y</ArticleId><ArticleId IdType="pii">10.1007/s00401-022-02471-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Chalabi A, Kwak S, Mehler M, Rouleau G, Siddique T, Strong M, et al. Genetic and epigenetic studies of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2013;14:44&#x2013;52. doi: 10.3109/21678421.2013.778571.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.778571</ArticleId><ArticleId IdType="pubmed">23678879</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade NS, Ramic M, Esanov R, Liu W, Rybin MJ, Gaidosh G, et al. Dipeptide repeat proteins inhibit homology-directed DNA double strand break repair in C9ORF72 ALS/FTD. Mol Neurodegener. 2020;15:13. doi: 10.1186/s13024-020-00365-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00365-9</ArticleId><ArticleId IdType="pmc">PMC7041170</ArticleId><ArticleId IdType="pubmed">32093728</ArticleId></ArticleIdList></Reference><Reference><Citation>Bampton A, Gittings LM, Fratta P, Lashley T, Gatt A. The role of hnRNPs in frontotemporal dementia and amyotrophic lateral sclerosis. Acta Neuropathol. 2020;140:599&#x2013;623. doi: 10.1007/s00401-020-02203-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02203-0</ArticleId><ArticleId IdType="pmc">PMC7547044</ArticleId><ArticleId IdType="pubmed">32748079</ArticleId></ArticleIdList></Reference><Reference><Citation>Bampton A, Gatt A, Humphrey J, Cappelli S, Bhattacharya D, Foti S, et al. HnRNP K mislocalisation is a novel protein pathology of frontotemporal lobar degeneration and ageing and leads to cryptic splicing. Acta Neuropathol. 2021;142:609&#x2013;627. doi: 10.1007/s00401-021-02340-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-021-02340-0</ArticleId><ArticleId IdType="pmc">PMC8423707</ArticleId><ArticleId IdType="pubmed">34274995</ArticleId></ArticleIdList></Reference><Reference><Citation>Berson A, Goodman LD, Sartoris AN, Otte CG, Aykit JA, Lee VMY, et al. Drosophila Ref1/ALYREF regulates transcription and toxicity associated with ALS/FTD disease etiologies. Acta Neuropathol Commun. 2019;7:65. doi: 10.1186/s40478-019-0710-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0710-x</ArticleId><ArticleId IdType="pmc">PMC6487524</ArticleId><ArticleId IdType="pubmed">31036086</ArticleId></ArticleIdList></Reference><Reference><Citation>Bill BR, Petzold AM, Clark KJ, Schimmenti LA, Ekker SC. A primer for morpholino use in zebrafish. Zebrafish. 2009;6:69&#x2013;77. doi: 10.1089/ZEB.2008.0555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ZEB.2008.0555</ArticleId><ArticleId IdType="pmc">PMC2776066</ArticleId><ArticleId IdType="pubmed">19374550</ArticleId></ArticleIdList></Reference><Reference><Citation>Bomsztyk K, Denisenko O, Ostrowski J. hnRNP K: one protein multiple processes. BioEssays. 2004;26:629&#x2013;638. doi: 10.1002/bies.20048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bies.20048</ArticleId><ArticleId IdType="pubmed">15170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Braddock DT, Baber JL, Levens D, Clore GM. Molecular basis of sequence-specific single-stranded DNA recognition by KH domains: Solution structure of a complex between hnRNP K KH3 and single-stranded DNA. EMBO J. 2002;21:3476&#x2013;3485. doi: 10.1093/emboj/cdf352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/cdf352</ArticleId><ArticleId IdType="pmc">PMC126100</ArticleId><ArticleId IdType="pubmed">12093748</ArticleId></ArticleIdList></Reference><Reference><Citation>Braems E, Swinnen B, Van Den Bosch L. C9orf72 loss-of-function: a trivial, stand-alone or additive mechanism in C9 ALS/FTD? Acta Neuropathol. 2020;140:625&#x2013;643. doi: 10.1007/s00401-020-02214-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02214-x</ArticleId><ArticleId IdType="pmc">PMC7547039</ArticleId><ArticleId IdType="pubmed">32876811</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Shaw PJ, Kirby J. The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype. Acta Neuropathol. 2014;127:333&#x2013;345. doi: 10.1007/s00401-014-1251-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1251-9</ArticleId><ArticleId IdType="pmc">PMC3925297</ArticleId><ArticleId IdType="pubmed">24493408</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Walsh MJ, Higginbottom A, Highley JR, Dickman MJ, Edbauer D, et al. Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions. Brain. 2014;137:2040&#x2013;2051. doi: 10.1093/brain/awu120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu120</ArticleId><ArticleId IdType="pmc">PMC4065024</ArticleId><ArticleId IdType="pubmed">24866055</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Higginbottom A, Stopford MJ, Highley JR, Ince PG, Wharton SB, et al. Antisense RNA foci in the motor neurons of C9ORF72-ALS patients are associated with TDP-43 proteinopathy. Acta Neuropathol. 2015;130:63&#x2013;75. doi: 10.1007/s00401-015-1429-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1429-9</ArticleId><ArticleId IdType="pmc">PMC4468790</ArticleId><ArticleId IdType="pubmed">25943887</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Angiolella V, Donato V, Forrester FM, Jeong YT, Pellacani C, Kudo Y, et al. Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell. 2012;149:1023&#x2013;1034. doi: 10.1016/j.cell.2012.03.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.03.043</ArticleId><ArticleId IdType="pmc">PMC3616325</ArticleId><ArticleId IdType="pubmed">22632967</ArticleId></ArticleIdList></Reference><Reference><Citation>Dedeene L, Van Schoor E, Race V, Moisse M, Vandenberghe R, Poesen K, et al. An ALS case with 38 (G4C2)-repeats in the C9orf72 gene shows TDP-43 and sparse dipeptide repeat protein pathology. Acta Neuropathol. 2019;137:855&#x2013;858. doi: 10.1007/S00401-019-01996-Z/FIGURES/1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00401-019-01996-Z/FIGURES/1</ArticleId><ArticleId IdType="pubmed">30919029</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Dols-Icardo O, Garc&#xed;a-Redondo A, Rojas-Garc&#xed;a R, S&#xe1;nchez-Valle R, Noguera A, G&#xf3;mez-Tortosa E, et al. Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. Hum Mol Genet. 2014;23:749&#x2013;754. doi: 10.1093/hmg/ddt460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt460</ArticleId><ArticleId IdType="pubmed">24057670</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, Zhang PW, Pham JT, Haeusler AR, Mistry NA, Vidensky S, et al. RNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention. Neuron. 2013;80:415&#x2013;428. doi: 10.1016/j.neuron.2013.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.10.015</ArticleId><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Taylor JP. The Role of Dipeptide Repeats in C9ORF72-Related ALS-FTD. Front Mol Neurosci. 2017;10:35. doi: 10.3389/fnmol.2017.00035.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00035</ArticleId><ArticleId IdType="pmc">PMC5303742</ArticleId><ArticleId IdType="pubmed">28243191</ArticleId></ArticleIdList></Reference><Reference><Citation>Fumagalli L, Young FL, Boeynaems S, De Decker M, Mehta AR, Swijsen A, et al. C9orf72-derived arginine-containing dipeptide repeats associate with axonal transport machinery and impede microtubule-based motility. Sci Adv. 2021;7:eabg3013. doi: 10.1126/SCIADV.ABG3013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/SCIADV.ABG3013</ArticleId><ArticleId IdType="pmc">PMC8034861</ArticleId><ArticleId IdType="pubmed">33837088</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallardo M, Hornbaker MJ, Zhang X, Hu P, Bueso-Ramos C, Post SM. Aberrant hnRNP K expression: all roads lead to cancer. Cell Cycle. 2016;15:1552&#x2013;1557. doi: 10.1080/15384101.2016.1164372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15384101.2016.1164372</ArticleId><ArticleId IdType="pmc">PMC4934053</ArticleId><ArticleId IdType="pubmed">27049467</ArticleId></ArticleIdList></Reference><Reference><Citation>Geuens T, Bouhy D, Timmerman V. The hnRNP family: insights into their role in health and disease. Hum Genet. 2016;135:851&#x2013;867. doi: 10.1007/s00439-016-1683-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00439-016-1683-5</ArticleId><ArticleId IdType="pmc">PMC4947485</ArticleId><ArticleId IdType="pubmed">27215579</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaves CV, Rohrer JD. An update on genetic frontotemporal dementia. J Neurol. 2019;266:2075&#x2013;2086. doi: 10.1007/s00415-019-09363-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09363-4</ArticleId><ArticleId IdType="pmc">PMC6647117</ArticleId><ArticleId IdType="pubmed">31119452</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, Naujock M, Fumagalli L, Vandoorne T, Baatsen P, Boon R, et al. HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nat Commun. 2017;8:861. doi: 10.1038/s41467-017-00911-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00911-y</ArticleId><ArticleId IdType="pmc">PMC5636840</ArticleId><ArticleId IdType="pubmed">29021520</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, Donnelly CJ, Periz G, Simko EAJ, Shaw PG, Kim MS, et al. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature. 2014;507:195&#x2013;200. doi: 10.1038/nature13124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13124</ArticleId><ArticleId IdType="pmc">PMC4046618</ArticleId><ArticleId IdType="pubmed">24598541</ArticleId></ArticleIdList></Reference><Reference><Citation>Harley J, Patani R. Stress-specific spatiotemporal responses of RNA-binding proteins in human stem-cell-derived motor neurons. Int J Mol Sci. 2020;21:8346. doi: 10.3390/ijms21218346.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21218346</ArticleId><ArticleId IdType="pmc">PMC7664327</ArticleId><ArticleId IdType="pubmed">33172210</ArticleId></ArticleIdList></Reference><Reference><Citation>He L, Xue X, Wang Z, Hou E, Liu Y, Liang M, et al. Transcriptional regulation of heterogeneous nuclear ribonucleoprotein K gene expression. Biochimie. 2015;109:27&#x2013;35. doi: 10.1016/j.biochi.2014.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biochi.2014.12.002</ArticleId><ArticleId IdType="pmc">PMC4414404</ArticleId><ArticleId IdType="pubmed">25497182</ArticleId></ArticleIdList></Reference><Reference><Citation>Kok JR, Palminha NM, Dos Santos SC, El-Khamisy SF, Ferraiuolo L. DNA damage as a mechanism of neurodegeneration in ALS and a contributor to astrocyte toxicity. Cell Mol Life Sci. 2021;78:5707&#x2013;5729. doi: 10.1007/s00018-021-03872-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-021-03872-0</ArticleId><ArticleId IdType="pmc">PMC8316199</ArticleId><ArticleId IdType="pubmed">34173837</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopka A, Whelan DR, Jamali MS, Perri E, Shahheydari H, Toth RP, et al. Impaired NHEJ repair in amyotrophic lateral sclerosis is associated with TDP-43 mutations. Mol Neurodegener. 2020;15:51. doi: 10.1186/s13024-020-00386-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00386-4</ArticleId><ArticleId IdType="pmc">PMC7488163</ArticleId><ArticleId IdType="pubmed">32907630</ArticleId></ArticleIdList></Reference><Reference><Citation>Lafarga V, Sirozh O, D&#xed;az-L&#xf3;pez I, Galarreta A, Hisaoka M, Zarzuela E, et al. Widespread displacement of DNA- and RNA-binding factors underlies toxicity of arginine-rich cell-penetrating peptides. EMBO J. 2021;40:e103311. doi: 10.15252/embj.2019103311.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2019103311</ArticleId><ArticleId IdType="pmc">PMC8246256</ArticleId><ArticleId IdType="pubmed">33978236</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird AS, van Hoecke A, De Muynck L, Timmers M, van den Bosch L, Van Damme P, et al. Progranulin is neurotrophic in vivo and protects against a mutant TDP-43 induced axonopathy. PLoS ONE. 2010;5:e13368. doi: 10.1371/journal.pone.0013368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0013368</ArticleId><ArticleId IdType="pmc">PMC2954192</ArticleId><ArticleId IdType="pubmed">20967127</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KH, Zhang P, Kim HJ, Mitrea DM, Sarkar M, Freibaum BD, et al. C9orf72 dipeptide repeats impair the assembly, dynamics, and function of membrane-less organelles. Cell. 2016;167:774&#x2013;788. doi: 10.1016/j.cell.2016.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.10.002</ArticleId><ArticleId IdType="pmc">PMC5079111</ArticleId><ArticleId IdType="pubmed">27768896</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemmens R, Van Hoecke A, Hersmus N, Geelen V, D&#x2019;Hollander I, Thijs V, et al. Overexpression of mutant superoxide dismutase 1 causes a motor axonopathy in the zebrafish. Hum Mol Genet. 2007;16:2359&#x2013;2365. doi: 10.1093/hmg/ddm193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddm193</ArticleId><ArticleId IdType="pubmed">17636250</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Chen Y, Xu X, Jones J, Tiwari M, Ling J, et al. HNRNPK maintains epidermal progenitor function through transcription of proliferation genes and degrading differentiation promoting mRNAs. Nat Commun. 2019;10:4198. doi: 10.1038/s41467-019-12238-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-12238-x</ArticleId><ArticleId IdType="pmc">PMC6744489</ArticleId><ArticleId IdType="pubmed">31519929</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Li Y, Hu R, Han W, Gao S. Knockdown of ribonucleotide reductase regulatory subunit M2 increases the drug sensitivity of chronic myeloid leukemia to imatinib-based therapy. Oncol Rep. 2019;42:571&#x2013;580. doi: 10.3892/or.2019.7194.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2019.7194</ArticleId><ArticleId IdType="pmc">PMC6610035</ArticleId><ArticleId IdType="pubmed">31233186</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Guo L, Qi H, Lou M, Wang R, Hai B, et al. A MYBL2 complex for RRM2 transactivation and the synthetic effect of MYBL2 knockdown with WEE1 inhibition against colorectal cancer. Cell Death Dis. 2021;12:683. doi: 10.1038/s41419-021-03969-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-021-03969-1</ArticleId><ArticleId IdType="pmc">PMC8263627</ArticleId><ArticleId IdType="pubmed">34234118</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubelsky Y, Ulitsky I. Sequences enriched in Alu repeats drive nuclear localization of long RNAs in human cells. Nature. 2018;555:107&#x2013;111. doi: 10.1038/nature25757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25757</ArticleId><ArticleId IdType="pmc">PMC6047738</ArticleId><ArticleId IdType="pubmed">29466324</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch EM, Robertson S, FitzGibbons C, Reilly M, Switalski C, Eckardt A, et al. Transcriptome analysis using patient iPSC-derived skeletal myocytes: Bet1L as a new molecule possibly linked to neuromuscular junction degeneration in ALS. Exp Neurol. 2021;345:113815. doi: 10.1016/j.expneurol.2021.113815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2021.113815</ArticleId><ArticleId IdType="pmc">PMC8429236</ArticleId><ArticleId IdType="pubmed">34310943</ArticleId></ArticleIdList></Reference><Reference><Citation>Mah LJ, El-Osta A, Karagiannis TC. &#x3b3;h2AX: a sensitive molecular marker of DNA damage and repair. Leukemia. 2010;24:679&#x2013;686. doi: 10.1038/leu.2010.6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2010.6</ArticleId><ArticleId IdType="pubmed">20130602</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, Renton AE, Mok K, Dopper EGP, Waite A, Rollinson S, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11:323&#x2013;330. doi: 10.1016/S1474-4422(12)70043-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70043-1</ArticleId><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Maor-Nof M, Shipony Z, Lopez-Gonzalez R, Nakayama L, Zhang YJ, Couthouis J, et al. p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR) Cell. 2021;184:689&#x2013;708. doi: 10.1016/j.cell.2020.12.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.12.025</ArticleId><ArticleId IdType="pmc">PMC7886018</ArticleId><ArticleId IdType="pubmed">33482083</ArticleId></ArticleIdList></Reference><Reference><Citation>Mar&#xed;n-B&#xe9;jar O, Huarte M. RNA pulldown protocol for in vitro detection and identification of RNA-associated proteins. Methods Mol Biol. 2015;1206:87&#x2013;95. doi: 10.1007/978-1-4939-1369-5_8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-1369-5_8</ArticleId><ArticleId IdType="pubmed">25240889</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy DJ, Chen Y, Smyth GK. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res. 2012;40:4288&#x2013;4297. doi: 10.1093/nar/gks042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks042</ArticleId><ArticleId IdType="pmc">PMC3378882</ArticleId><ArticleId IdType="pubmed">22287627</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta AR, Gregory JM, Dando O, Carter RN, Burr K, Nanda J, et al. Mitochondrial bioenergetic deficits in C9orf72 amyotrophic lateral sclerosis motor neurons cause dysfunctional axonal homeostasis. Acta Neuropathol. 2021;141:257&#x2013;279. doi: 10.1007/s00401-020-02252-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02252-5</ArticleId><ArticleId IdType="pmc">PMC7847443</ArticleId><ArticleId IdType="pubmed">33398403</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Lashley T, Norona FE, Clayton EL, Ridler CE, Fratta P, et al. C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol. 2013;126:845&#x2013;857. doi: 10.1007/s00401-013-1200-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1200-z</ArticleId><ArticleId IdType="pmc">PMC3830745</ArticleId><ArticleId IdType="pubmed">24170096</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Gr&#xf6;nke S, Niccoli T, Ridler CE, Clayton EL, Devoy A, et al. C9orf72 repeat expansions cause neurodegeneration in drosophila through arginine-rich proteins. Science. 2014;345:1192&#x2013;1194. doi: 10.1126/science.1256800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1256800</ArticleId><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Nihei Y, Arzberger T, Zhou Q, Mackenzie IR, Hermann A, et al. Reduced hnRNPA3 increases C9orf72 repeat RNA levels and dipeptide-repeat protein deposition. EMBO Rep. 2016;17:1314&#x2013;1325. doi: 10.15252/embr.201541724.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201541724</ArticleId><ArticleId IdType="pmc">PMC5007570</ArticleId><ArticleId IdType="pubmed">27461252</ArticleId></ArticleIdList></Reference><Reference><Citation>Moujalled D, James JL, Yang S, Zhang K, Duncan C, Moujalled DM, et al. Phosphorylation of hnRNP K by cyclin-dependent kinase 2 controls cytosolic accumulation of TDP-43. Hum Mol Genet. 2015;24:1655&#x2013;1669. doi: 10.1093/hmg/ddu578.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu578</ArticleId><ArticleId IdType="pubmed">25410660</ArticleId></ArticleIdList></Reference><Reference><Citation>Moujalled D, Grubman A, Acevedo K, Yang S, Ke YD, Moujalled DM, et al. TDP-43 mutations causing amyotrophic lateral sclerosis are associated with altered expression of RNA-binding protein hnRNP K and affect the Nrf2 antioxidant pathway. Hum Mol Genet. 2017;26:1732&#x2013;1746. doi: 10.1093/hmg/ddx093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx093</ArticleId><ArticleId IdType="pubmed">28334913</ArticleId></ArticleIdList></Reference><Reference><Citation>Moumen A, Magill C, Dry KL, Jackson SP. ATM-dependent phosphorylation of heterogeneous nuclear ribonucleoprotein K promotes p53 transcriptional activation in response to DNA damage. Cell Cycle. 2013;12:698&#x2013;704. doi: 10.4161/cc.23592.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cc.23592</ArticleId><ArticleId IdType="pmc">PMC3594270</ArticleId><ArticleId IdType="pubmed">23343766</ArticleId></ArticleIdList></Reference><Reference><Citation>Moumen A, Masterson P, O&#x2019;Connor MJ, Jackson SP. hnRNP K: An HDM2 target and transcriptional coactivator of p53 in response to DNA damage. Cell. 2005;123:1065&#x2013;1078. doi: 10.1016/j.cell.2005.09.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2005.09.032</ArticleId><ArticleId IdType="pubmed">16360036</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng ASL, Rademakers R, Miller BL. Frontotemporal dementia: a bridge between dementia and neuromuscular disease. Ann NY Acad Sci. 2015;1338:71&#x2013;93. doi: 10.1111/nyas.12638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nyas.12638</ArticleId><ArticleId IdType="pmc">PMC4399703</ArticleId><ArticleId IdType="pubmed">25557955</ArticleId></ArticleIdList></Reference><Reference><Citation>Nihei Y, Mori K, Werner G, Arzberger T, Zhou Q, Khosravi B, et al. Poly-glycine&#x2013;alanine exacerbates C9orf72 repeat expansion-mediated DNA damage via sequestration of phosphorylated ATM and loss of nuclear hnRNPA3. Acta Neuropathol. 2020;139:99&#x2013;118. doi: 10.1007/s00401-019-02082-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02082-0</ArticleId><ArticleId IdType="pmc">PMC6942035</ArticleId><ArticleId IdType="pubmed">31642962</ArticleId></ArticleIdList></Reference><Reference><Citation>Niida H, Katsuno Y, Sengoku M, Shimada M, Yukawa M, Ikura M, et al. Essential role of Tip60-dependent recruitment of ribonucleotide reductase at DNA damage sites in DNA repair during G1 phase. Genes Dev. 2010;24:333&#x2013;338. doi: 10.1101/gad.1863810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1863810</ArticleId><ArticleId IdType="pmc">PMC2816732</ArticleId><ArticleId IdType="pubmed">20159953</ArticleId></ArticleIdList></Reference><Reference><Citation>Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14:417&#x2013;419. doi: 10.1038/nmeth.4197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4197</ArticleId><ArticleId IdType="pmc">PMC5600148</ArticleId><ArticleId IdType="pubmed">28263959</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelisch F, Pozzi B, Risso G, Mu&#xf1;oz MJ, Srebrow A. DNA damage-induced heterogeneous nuclear ribonucleoprotein K SUMOylation regulates p53 transcriptional activation. J Biol Chem. 2012;287:30789&#x2013;30799. doi: 10.1074/jbc.M112.390120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.390120</ArticleId><ArticleId IdType="pmc">PMC3436322</ArticleId><ArticleId IdType="pubmed">22825850</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, Belzil VV, Batra R, Ross CA, Gendron TF, Pregent LJ, et al. Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nat Neurosci. 2015;18:1175&#x2013;1182. doi: 10.1038/nn.4065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4065</ArticleId><ArticleId IdType="pmc">PMC4830686</ArticleId><ArticleId IdType="pubmed">26192745</ArticleId></ArticleIdList></Reference><Reference><Citation>Purice MD, Taylor JP. Linking hnRNP function to ALS and FTD pathology. Front Neurosci. 2018;12:326. doi: 10.3389/fnins.2018.00326.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00326</ArticleId><ArticleId IdType="pmc">PMC5962818</ArticleId><ArticleId IdType="pubmed">29867335</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chi&#xf2; A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17:17&#x2013;23. doi: 10.1038/nn.3584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3584</ArticleId><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Sim&#xf3;n-S&#xe1;nchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010.A</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvaraj BT, Livesey MR, Zhao C, Gregory JM, James OT, Cleary EM, et al. C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca2+-permeable AMPA receptor-mediated excitotoxicity. Nat Commun. 2018;9:347. doi: 10.1038/s41467-017-02729-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02729-0</ArticleId><ArticleId IdType="pmc">PMC5783946</ArticleId><ArticleId IdType="pubmed">29367641</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah KN, Wilson EA, Malla R, Elford HL, Faridi JS. Targeting ribonucleotide reductase M2 and NF-&#x3ba;B activation with didox to circumvent tamoxifen resistance in breast cancer. Mol Cancer Ther. 2015;14:2411&#x2013;2421. doi: 10.1158/1535-7163.MCT-14-0689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.MCT-14-0689</ArticleId><ArticleId IdType="pubmed">26333382</ArticleId></ArticleIdList></Reference><Reference><Citation>Stickeler E, Fraser SD, Honig A, Chen AL, Berget SM, Cooper TA. The RNA binding protein YB-1 binds A/C-rich exon enhancers and stimulates splicing of the CD44 alternative exon v4. EMBO J. 2001;20:3821&#x2013;3830. doi: 10.1093/emboj/20.14.3821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/20.14.3821</ArticleId><ArticleId IdType="pmc">PMC125550</ArticleId><ArticleId IdType="pubmed">11447123</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B, Bento-Abreu A, Gendron TF, Boeynaems S, Bogaert E, Nuyts R, et al. A zebrafish model for C9orf72 ALS reveals RNA toxicity as a pathogenic mechanism. Acta Neuropathol. 2018;135:427&#x2013;443. doi: 10.1007/s00401-017-1796-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1796-5</ArticleId><ArticleId IdType="pubmed">29302778</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol. 2014;10:661&#x2013;670. doi: 10.1038/nrneurol.2014.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.184</ArticleId><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B, Robberecht W, Van Den Bosch L. RNA toxicity in non-coding repeat expansion disorders. EMBO J. 2020;39:e101112. doi: 10.15252/embj.2018101112.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2018101112</ArticleId><ArticleId IdType="pmc">PMC6939197</ArticleId><ArticleId IdType="pubmed">31721251</ArticleId></ArticleIdList></Reference><Reference><Citation>Trabzuni D, Wray S, Vandrovcova J, Ramasamy A, Walker R, Smith C, et al. MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies. Hum Mol Genet. 2012;21:4094&#x2013;4103. doi: 10.1093/hmg/dds238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds238</ArticleId><ArticleId IdType="pmc">PMC3428157</ArticleId><ArticleId IdType="pubmed">22723018</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyzack GE, Neeves J, Crerar H, Klein P, Ziff O, Taha DM, et al. Aberrant cytoplasmic intron retention is a blueprint for RNA binding protein mislocalization in VCP-related amyotrophic lateral sclerosis. Brain. 2021;144:1985&#x2013;1993. doi: 10.1093/brain/awab078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab078</ArticleId><ArticleId IdType="pmc">PMC8370440</ArticleId><ArticleId IdType="pubmed">33693641</ArticleId></ArticleIdList></Reference><Reference><Citation>Tziortzouda P, Van Den Bosch L, Hirth F. Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation. Nat Rev Neurosci. 2021;22:197&#x2013;208. doi: 10.1038/s41583-021-00431-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-021-00431-1</ArticleId><ArticleId IdType="pubmed">33654312</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Blitterswijk M, Mullen B, Wojtas A, Heckman MG, Diehl NN, Baker MC, et al. Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene. Mol Neurodegener. 2014;9:38. doi: 10.1186/1750-1326-9-38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-9-38</ArticleId><ArticleId IdType="pmc">PMC4190282</ArticleId><ArticleId IdType="pubmed">25239657</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Der Ende EL, Jackson JL, White A, Seelaar H, Van Blitterswijk M, Van Swieten JC. Unravelling the clinical spectrum and the role of repeat length in C9ORF72 repeat expansions. J Neurol Neurosurg Psychiatry. 2021;92:502&#x2013;509. doi: 10.1136/jnnp-2020-325377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-325377</ArticleId><ArticleId IdType="pmc">PMC8053328</ArticleId><ArticleId IdType="pubmed">33452054</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Gils M, Vanakker OM. Morpholino-mediated gene knockdown in zebrafish: it is all about dosage and validation. J Invest Dermatol. 2019;139:1599&#x2013;1600. doi: 10.1016/J.JID.2019.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JID.2019.01.017</ArticleId><ArticleId IdType="pubmed">30707900</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hoecke A, Schoonaert L, Lemmens R, Timmers M, Staats KA, Laird AS, et al. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med. 2012;18:1418&#x2013;1422. doi: 10.1038/nm.2901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2901</ArticleId><ArticleId IdType="pubmed">22922411</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Nostrand EL, Freese P, Pratt GA, Wang X, Wei X, Xiao R, et al. A large-scale binding and functional map of human RNA-binding proteins. Nature. 2020;583:711&#x2013;719. doi: 10.1038/s41586-020-2077-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2077-3</ArticleId><ArticleId IdType="pmc">PMC7410833</ArticleId><ArticleId IdType="pubmed">32728246</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Musich PR, Cui K, Zou Y, Zhu MY. Neurotoxin-Induced DNA Damage is Persistent in SH-SY5Y Cells and LC Neurons. Neurotox Res. 2015;27:368&#x2013;383. doi: 10.1007/s12640-015-9521-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-015-9521-4</ArticleId><ArticleId IdType="pmc">PMC4385397</ArticleId><ArticleId IdType="pubmed">25724887</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Qiu H, He J, Liu L, Xue W, Fox A, et al. The emerging roles of hnRNPK. J Cell Physiol. 2020;235:1995&#x2013;2008. doi: 10.1002/jcp.29186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.29186</ArticleId><ArticleId IdType="pubmed">31538344</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiesmann N, Strozynski J, Beck C, Zimmermann N, Mendler S, Gieringer R, et al. Knockdown of hnRNPK leads to increased DNA damage after irradiation and reduces survival of tumor cells. Carcinogenesis. 2017;38:321&#x2013;328. doi: 10.1093/carcin/bgx006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/carcin/bgx006</ArticleId><ArticleId IdType="pubmed">28426877</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin S, Lopez-Gonzalez R, Kunz RC, Gangopadhyay J, Borufka C, Gygi SP, et al. Evidence that C9ORF72 dipeptide repeat proteins associate with U2 snRNP to cause mis-splicing in ALS/FTD patients. Cell Rep. 2017;19:2244&#x2013;2256. doi: 10.1016/j.celrep.2017.05.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.05.056</ArticleId><ArticleId IdType="pmc">PMC5653973</ArticleId><ArticleId IdType="pubmed">28614712</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YW, Jones TL, Martin SE, Caplen NJ, Pommier Y. Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response. J Biol Chem. 2009;284:18085&#x2013;18095. doi: 10.1074/jbc.M109.003020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.003020</ArticleId><ArticleId IdType="pmc">PMC2709352</ArticleId><ArticleId IdType="pubmed">19416980</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>